Policymakers should make better use of the 340B program to help eliminate “pharmacy deserts” in Black and Hispanic/Latino urban neighborhoods, new research published in Health Affairs recommends.
The study was conducted by researchers at four universities and supported by the
…
Commercially insured patients with deductibles and coinsurance pay more when manufacturers raise a drug’s list price and do not directly benefit from the confidential rebates paid by manufacturers to insurers, according to a study published this morning in JAMA Open
…
Between 3% and 5% of 340B drug discounts and Medicaid drug rebates are duplicates, adding up to at least $933 million and potentially as high as $1.6 billion in additional costs to the pharmaceutical industry in 2019, according to new
…
340B hospitals provide “a significantly higher average number” of medication access (MA) services—such as free or discounted drugs or free delivery—than comparably sized non-340B hospitals, a new academic study shows.
The study was conducted by the University of Illinois Chicago
…
A study published online by Health Affairs yesterday on nonprofit hospitals’ provision of charity care could renew drug manufacturers’ calls for more control over those hospitals’ participation in the 340B program.
Professors and scientists at The Johns Hopkins University used
…
Medicare Part B drug payments to 340B hospitals “declined substantially” in 2019 because the payment status of “an unusually high number of drugs” changed that year, congressional Medicare advisers said in a report yesterday.
The change—from “pass-through status” to “separately
…*Sign up for news summaries and alerts from 340B Report